That a marked difference in CK18 immunostaining was seen between pTa and pT2-4 urothelial carcinomas is consistent with the striking genomic differences between these tumor categories (summarized in (Knowles and Hurst 2015)). This evidence concerns the gene KRT18 and urothelial carcinoma.